M
Mimetas
Developing physiologically relevant 3D human disease models and partnering with global pharmaceutical companies to create therapies for untreatable diseases
About Mimetas
Mimetas is a biotechnology company that develops organ-on-a-chip and 3D human tissue models for drug discovery and development. Its OrganoPlate® platform enables the creation of perfused vascular, epithelial, and connective tissue models for pharmaceutical research.
Mimetas provides research services and products to pharmaceutical and biotechnology companies, supporting drug efficacy and safety testing across immunology, infectious disease, metabolic disease, oncology, neurology, and ADME/tox studies. The company also offers OrganoAccess™, a perfusable vascular bed system for 3D tissue modeling.
Founded in 2013 in Leiden, the Netherlands, Mimetas operates offices in the Netherlands, the United States, and Japan. It is a spinout from Leiden University and the University of Freiburg.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Oegstgeest, Netherlands
- Employees
- 99
- Open positions
- None listed
- Dealroom signal
- 86.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Medical Research, Drug Development, Microfluidics, Tissue Engineering
- Technology
- Artificial Intelligence, 3D Technology, Deep Learning, Computer Vision
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Aug 2026 | $0 | — | Bruker | ↗ |
| GRANT✓Other financing | Jan 2022 | $1.3M | — | Nc3rs | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Mimetas is 15K monthly website visits, up 25% over the last three months. Mimetas's team grew 7.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Nc3rs
Series A7 investors entered at this stage
Zeeuws InvesteringsFonds
Oost NL - Eastern Netherlands Regional Development Agency
Aglaia BioMedical Ventures
InnovationQuarter Capital- EFEuropean Life Sciences Growth Fund
Korys
Cathay Venture
Other known investors8 additional known investors
Bruker
Leiden University
University of Freiburg
BioHealth Innovation
KIKK Capital
Libertatis Ergo Holding
Maryland Industrial Partnerships
Mérieux Equity Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mimetas on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mimetas’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.